TD Asset Management
EIKN

TD Asset Management’s Eikon Therapeutics EIKN Stock Holding History

TD Asset Management’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$745K Hold
57,074
– – ﹤0.01% 1137
2026
Q1 		$604K Buy
+57,074
New +$763K ﹤0.01% 1156

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TD Asset Management's EIKN Position: Q2 2026 in Review

TD Asset Management held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 57,074 shares worth $745K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

TD Asset Management first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • TD Asset Management held 57,074 shares of Eikon Therapeutics worth $745K as of Q2 2026.
  • TD Asset Management left its Eikon Therapeutics share count unchanged in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1137 holding.
  • TD Asset Management first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.